cyclosporin + sodium zirconium cyclosilicate

This is a **combination of cyclosporin and sodium zirconium cyclosilicate**, administered concurrently or in close temporal proximity. **Cyclosporin** is a calcineurin inhibitor immunosuppressant primarily used for preventing transplant rejection and treating some autoimmune disorders. It inhibits T-cell activation by blocking calcineurin, thus preventing the transcription of interleukin-2 and other cytokines. **Sodium zirconium cyclosilicate (SZC)** is a non-absorbed, selective potassium binder used to treat hyperkalemia. It acts by exchanging sodium and hydrogen ions for potassium ions in the gastrointestinal tract, thereby lowering serum potassium. The combination is relevant for kidney transplant or other patients who need immunosuppression (with cyclosporin) and require potassium management (with SZC), especially given that cyclosporin can contribute to hyperkalemia. Pharmacokinetic studies show **SZC does not affect cyclosporin exposure** but does reduce absorption of certain other drugs with pH-dependent bioavailability, and so cyclosporin may generally be given together with SZC without dose adjustment[1][3][5].